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Background: To date, few PET tracers for in vivo labeling of red blood cells (RBCs) are available. In this study, we
report the radiosynthesis and in vitro and in vivo evaluation of 11C and 18F sulfonamide derivatives targeting
carbonic anhydrase II (CA II), a metallo-enzyme expressed in RBCs, as potential blood pool tracers. A
proof-of-concept in vivo imaging study was performed to demonstrate the feasibility to assess cardiac function and
volumes using electrocardiogram (ECG)-gated positron emission tomography (PET) acquisition in comparison with
cine magnetic resonance imaging (cMRI) in rats and a pig model of myocardial infarction.
Methods: The inhibition constants (Ki) of CA II were determined in vitro for the different compounds by assaying
CA-catalyzed CO2 hydration activity. Binding to human RBCs was estimated after in vitro incubation of the
compounds with whole blood. Biodistribution studies were performed to evaluate tracer kinetics in NMRI mice.
ECG-gated PET acquisition was performed in Wistar rats at rest and during pharmacological stress by infusing
dobutamine at 10 μg/kg/min and in a pig model of myocardial infarction. Left ventricular ejection fraction (LVEF)
and volumes were compared with values from cMRI.
Results: The Ki of the investigated compounds for human CA II was found to be in the range of 8 to 422 nM. The
fraction of radioactivity associated with RBCs was found to be ≥90% at 10- and 60-min incubation of tracers with
heparinized human blood at room temperature for all tracers studied. Biodistribution studies in mice indicated that
30% to 67% of the injected dose was retained in the blood pool at 60 min post injection. A rapid and sustained
tracer uptake in the heart region with an average standardized uptake value of 2.5 was observed from micro-PET
images. The LVEF values obtained after pharmacological stress in rats closely matched between the cMRI and
micro-PET values, whereas at rest, a larger variation between LVEF values obtained by both techniques was
observed. In the pig model, a good agreement was observed between PET and MRI for quantification of left
ventricular volumes and ejection fraction.
Conclusions: The 11C and 18F sulfonamide derivatives can be used for efficient in vivo radiolabeling of RBCs, and
proof-of-concept in vivo imaging studies have shown the feasibility and potential of these novel tracers to assess
cardiac function.
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Radiolabeled red blood cells (RBCs) are used in the as-
sessment of blood pool dynamics, for investigating
angiofibroma and gastrointestinal hemorrhage and for
localizing intramuscular hemangioma [1-5]. To date,
very few positron emission tomography (PET) tracers
have been reported as RBC labeling agents. 68Ga-oxine
has been used for the labeling of RBCs, but this requires
an in vitro labeling procedure [6]. Examples of agents
for in vivo RBC labeling are 11CO and C15O in gaseous
form [7-9]. Due to in vivo instability and as a require-
ment of the sophisticated equipment for inhalation of
these tracer gases, extensive usage of these tracers in
preclinical or clinical studies is limited. Recently, human
serum albumin (HSA) and rat serum albumin (RSA)
were labeled with 62Cu and 68Ga, but one of the limita-
tions with 62Cu is the in vivo instability of the complex,
and 68Ga-DOTA-HSA has yet to prove its clinical appli-
cation [10-12].
Radiolabeling of rat and human RBCs by specific
enzyme-inhibitor approach was first reported in 1991 by
Singh et al. with 123I- or 125I-labeled p-iodobenzenesulfo-
namide targeting carbonic anhydrase I and II (CA I and
II), a metalloenzyme found in RBCs [13,14]. The authors
found that the activity associated with RBCs decreased
to about 50% of the injected dose (ID) at 24 h post injec-
tion (p.i.) in rats, whereas more than 88% of the ID
remained associated with RBCs at 24 h p.i. in human
volunteers. Fluorine-18 has appealing characteristics as a
radionuclide for PET as large batches (>500 GBq) of
fluorine-18 can be produced by current cyclotrons, and
the half-life of 110 min allows distribution from the pro-
duction site to multiple remote PET sites.
The short half-life of carbon-11 precludes its distribu-
tion but results in lower radiation burden to the patient
and allows the combination of scans with different PET
tracers in a 1-day protocol.
In this study, we report the evaluation of 11C- and 18F-
labeled sulfonamides for in vitro and in vivo labeling of
RBCs. In addition, a proof-of-concept in vivo imaging
study was carried out with 4-(2-[18F]fluoroethoxy)benze-
nesulfonamide, [18F]-(5), to assess the feasibility to cal-
culate left ventricular (LV) volumes and ejection fraction
(EF) in comparison with cine magnetic resonance im-
aging (cMRI). Currently, LV function and volumes are
most commonly assessed by conventional equilibrium-
gated radionuclide angiography and echocardiography.
The latter is a widely available technique with easy ac-
cess but is limited by a high inter- and intra-observer
variability and compromised echogenicity in obese
patients. More recently, the cMRI technique is more
widely used in clinical routine to estimate left ventricular
ejection fraction (LVEF) values and heart function, espe-
cially in patients with dilated or distorted ventricles, dueto its high-resolution functional images. Echocardio-
graphy and MRI are based on several assumptions of LV
geometry which may not hold true in dysfunctional LV
in contrast with radionuclide-based techniques that are
less dependent on geometrical assumptions. In addition,
for patients with pacemakers, defibrillators, or other
implanted electronic devices that preclude cMRI, PET
imaging offers a valuable alternative for cMRI. There-
fore, PET blood pool agents that have a potential to




In detail description of synthesis of precursors, reference
analogs (1 to 5) and production of the secondary radi-
olabeling agents 11CH3I and
18FEtBr are summarized in
Additional file 1.
4-(2-[18F]fluoroethoxy)benzoyl
aminoethylbenzenesulfonamide [18F]-(3) and 4-[11C]
methoxybenzoyl aminoethylbenzenesulfonamide [11C]-(4)
The synthons 11CH3I or
18FEtBr were bubbled into a so-
lution consisting of the phenolic precursor, 4-hydroxy-
N-[2-(4-sulfamoylphenyl)ethyl]benzamide (2, 0.2 mg)
and Cs2CO3 (1 to 2 mg) in anhydrous dimethylforma-
mide (DMF). The reaction mixture was heated at 90°C
for 5 min (11CH3I) or 15 min (
18FEtBr). The reaction
mixture was diluted with water (1 mL) and injected onto
a high-performance liquid chromatography (HPLC) sys-
tem (XBridge C18 column, 5 μm, 4.6 × 150 mm; Waters
Corporation, Milford, MA, USA) eluted with a mixture
of 0.05 M NaOAc (pH 5.5) and EtOH (80:20 v/v) at a
flow rate of 1 mL/min. UV detection of the HPLC eluate
was performed at 254 nm. The radiolabeled product
[18F]-(3) was collected after 15 min and [11C]-(4) eluted
11 min after injection on the HPLC system. The col-
lected peak corresponding to the desired radioligand was
then diluted with saline (Mini PlascoW, Braun, Melsungen,
Germany) to obtain a final EtOH concentration of ≤5%,
and the solution was filtered through a sterile 0.22-μm
membrane filter (MillexW-GV, Millipore Co., Billerica,
MA, USA). Quality control was performed on an analyt-
ical HPLC system consisting of an XBridge C18 column
(3.5 μm, 3 × 100 mm; Waters Corporation) eluted with a
mixture of 0.05 M NaOAc buffer (pH 5.5) and acetonitrile
(80:20 v/v) at a flow rate of 0.8 mL/min. UV detection was
performed at 254 nm. The tracers [18F]-(3) and [11C]-(4)
were eluted at 10 and 5 min, respectively, and their iden-
tity was confirmed by co-elution with authentic nonra-
dioactive reference solutions. The tracers [18F]-(3) and
[11C]-(4) were synthesized with a decay-corrected radio-
chemical yield of 45% and 30% (n = 3), respectively (rela-
tive to the starting radioactivity of 18FEtBr and 11CH3I),
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18FEtBr and 11CH3I, the synthesis time to obtain the pure
product was 50 ± 10 min for [18F]-(3) and 40 ± 5 min for
[11C]-(4). The average specific activity was found to be in




The synthons 18FEtBr or 11CH3I were bubbled into a
solution of the phenolic precursor 4-hydroxybenzene-
1-sulfonamide (0.8 mg) in a mixture of 1 M NaOH
(2.5 μL) and DMF (0.3 mL). The mixture was heated at
90°C for 5 min (11CH3I) or 15 min (
18FEtBr). The crude
mixture was diluted with water (1 mL) and injected onto
an HPLC column (XTerra C18, 5 μm, 7.8 × 150 mm;
Waters Corporation) eluted with a mixture of 0.05 M
NH4OAc (pH 6.8) and EtOH (90:10 v/v) at a flow rate of
2 mL/min. UV detection of the HPLC eluate was per-
formed at 254 nm. The radiolabeled product [18F]-(5) was
collected after 16 min, and [11C]-(6) was eluted after 15
min on the HPLC system. The collected peak correspond-
ing to the desired radioligand was then diluted with saline
(Mini PlascoW, Braun, Melsungen, Germany) to obtain a
final EtOH concentration of ≤5%, and the solution was
sterile filtered through a 0.22-μm membrane filter
(MillexW-GV, Millipore Co.). QC was performed on an
analytical HPLC system consisting of an XTerra C18 col-
umn (5 μm, 4.6 × 250 mm; Waters Corporation). For
[18F]-(5), the mobile phase was a mixture of 0.05 M
NH4OAc (pH 6.8) and EtOH (80:20 v/v); for [
11C]-(6), a
mixture of 0.05 M NH4OAc (pH 6.8) and acetonitrile
(80:20 v/v) was used. The flow rate was 0.9 mL/min. UV
detection was performed at 254 nm. The tracers [18F]-(5)
and [11C]-(6) were eluted at 11 and 9 min, respectively,
and the identity of the tracers was confirmed by co-
elution with authentic nonradioactive reference solutions.
The tracers [18F]-(5) and [11C]-(6) were synthesized with a
decay-corrected radiochemical yield of 65% (n = 3) and
with a radiochemical purity of ≥98%. Starting from
18FEtBr and 11CH3I, the synthesis time to obtain the pure
product was 55 ± 10 min for [18F]-(5) and 50 ± 5 min for
[11C]-(6). The average specific activity for both tracers was
found to be 90 GBq/μmol at the EOS.
In vitro studies
Log D (1-octanol/phosphate buffer pH 7.4)
Determination of the distribution coefficient (log D1-octa-
nol/phosphate buffer pH 7.4), was carried out by a shake flask
method [15]. An aliquot (25 μL) of the tracer agents
[18F]-(3), [11C]-(4), [18F]-(5), or [11C]-(6) (185 to 555
kBq/mL) was added to a polypropylene tube (5 mL;
Sarstedt, Nümbrecht, Germany) containing 2 mL of
0.025 M sodium phosphate buffer pH 7.4 and 2 mL of1-octanol. The tube was vortexed for 2 min at room
temperature followed by centrifugation at 3,000 rpm for
10 min (Eppendorf centrifuge 5810, Eppendorf,
Westbury, NY, USA). Aliquots of 50 μL of the 1-octanol
phase and 500 μL of the phosphate buffer phase were
pipetted into separate tared Eppendorf tubes with adequate
care to avoid cross contamination between the two phases.
The samples were weighed, and radioactivity was quantified
using an automated gamma counter. The experiments were
carried out sixfold.
Determination of inhibition constant
The inhibition constants (Ki) of the reference analogs
(3), (4), (5), and (6) against human CA (hCA) I and II
isozymes were determined by assaying the CA-catalyzed
CO2 hydration activity [16], using Applied Photophysics'
(Leatherhead, UK) stopped-flow instrument. Phenol red
(0.2 mM) was used as indicator, working at the absorb-
ance maximum of 557 nm, with 10 mM Hepes as buffer
(pH 7.5) and 0.1 M Na2SO4 (for maintaining constant
ionic strength) at 25°C following the CA-catalyzed CO2
hydration reaction for a period of 10 to 100 s (the unca-
talyzed reaction needs around 60 to 100 s under assay
conditions, whereas the catalyzed reactions take around
6 to 10 s). The CO2 concentrations ranged from 1.7 to
17 mM for the determination of kinetic parameters.
Each compound was tested in the concentration range
between 0.01 nM to 100 μM. The uncatalyzed rates were
determined in the same manner and subtracted from the
total observed rates. Stock solutions of the compounds
(0.1 mM) were prepared in distilled water with 10% to
20% (v/v) DMSO (which is non-inhibitory at these
concentrations), and dilutions up to 0.01 nM were
made with distilled water. Inhibitor and enzyme solu-
tions were preincubated together for 15 min at room
temperature prior to the assay, in order to allow the
formation of enzyme-inhibitor complex. The inhib-
ition constants were obtained by nonlinear least
square methods using PRISM 3 (GraphPad Software,
La Jolla, CA, USA), and they represent the mean from at
least three different determinations.
Whole blood analysis
Blood samples from a healthy human volunteer were
collected in a BD vacutainer™ (4.5 mL; containing lith-
ium heparin; BD, Franklin Lakes, NJ, USA). Aliquots of
whole blood (0.4 mL) were incubated with [11C]-(4) or
[11C]-(6) (370 kBq/0.1 mL) for 10 min and with [18F]-(3)
or [18F]-(5) (37 kBq/0.1 mL) for 60 min at room
temperature. A different incubation time with 11C and
18F tracer agents was used considering the radionuclides'
half-life (11C, 20 min; 18F, 110 min). After incubation for
10 or 60 min, the plasma was separated from the blood
cells by centrifugation at 3,000 rpm (1,837×g) for 5 min
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and unbound tracer from the RBCs, phosphate-buffered
saline (PBS) pH 7.4 (0.4 mL) was added to the cell frac-
tion. After incubation for 2 min, the PBS was separated
from the RBCs using centrifugation. This rinsing pro-
cedure was carried out twice. For competition studies
with acetazolamide (AAZ), the same procedure was fol-
lowed as mentioned afore. To the whole blood and
tracer agent mixture, a solution of AAZ (0.1 mL) was
added to result final concentrations of 0.01, 0.1, 0.2, 0.3,
0.4, 0.5, and 1.0 mM, and as a control, PBS (0.1 mL, PBS
pH 7.4) was added. The radioactivity associated with the
RBCs and plasma was quantified using an automated
gamma counter.
Distribution of activity within the blood
Human blood (12 mL) was collected in a syringe con-
taining 2.4 mL ACD (citrate-dextrose solution), and 3.7
MBq was added and gently mixed. Two milliliters of a
2% methylcellulose was added, gently mixed, and
allowed to stand for 60 min so that the RBCs sediment
by gravity. The supernatant was carefully drawn and
centrifuged at 1,000 rpm (140×g) for 5 min. The plasma-
rich supernatant and white blood cell (WBC)-rich pellet
were separated [17]. The activity in the three fractions
was counted using an automated gamma counter. The
procedure was carried out in triplicate.
In vivo studies
Biodistribution studies
The biodistribution studies were performed in wild-type
NMRI mice with body weights ranging from 30 to 40 g.
Mice were intravenously injected with 0.1 MBq of [18F]-
(3) or [18F]-(5) and 5.5 MBq of [11C]-(4) or [11C]-(6)
under anesthesia (2% isoflurane in O2 at a flow rate of 1
L/min). The animals were killed by decapitation at 2
min or 60 min p.i. (n = 4/time point for [18F]-(3), [11C]-
(4), and [11C]-(6); n = 6 for [18F]-(5)). Blood was
collected, and all major organs were dissected and col-
lected in tarred tubes and were weighed. The radioactiv-
ity in each organ was counted using an automated
gamma counter, corrected for background radioactivity
and expressed as follows: percentage of the injected dose
(% ID) or as standardized uptake value (SUV) (SUV =
(Counts in tissue per gram of tissue) / (Injected counts
per total body mass (g)). For the calculation of total
radioactivity in the blood, blood mass was assumed to
be 7% of the body mass [18].
Small animal imaging studies
PET images were acquired on a FOCUS 220 tomograph
(Siemens/Concorde Microsystems, Knoxville, TN, USA).
During all scan sessions, rats were anesthetized (2.5%
isoflurane in O2 at a flow rate of 1 L/min) and scannedin prone position. [18F]-(5) (37 MBq) was administered
via the tail vein, and a 1-h dynamic scan was acquired.
The images were acquired in list mode and binned in
sinograms using a 21-dynamic frame protocol (4 × 15, 4 ×
60, 5 × 180, 8 × 300 s). Reconstruction was performed
with the Focus 220 software (using Fourier rebinning, fol-
lowed by two-dimensional (2D) OSEM algorithm), and
data were analyzed using PMOD (version 2.65; PMOD,
Zurich, Switzerland). The radioactivity concentration in
the heart region was expressed as SUVs as a function of
time after injection of the radiotracer.
An electrocardiogram (ECG)-gated micro-PET scan
was performed with anesthetized (2.5% isoflurane in O2
at a flow rate of 1 L/min) Wistar rats (n = 2) after ad-
ministration of 48 MBq/0.7 mL of [18F]-(5) via the tail
vein. The acquisition was carried out at rest (0.5 h) and
stress (0.5 h) by infusion of dobutamine at 10 μg/kg/min.
The acquired data were reconstructed into a series of 12
ECG-gated images. To reduce noise, images were filtered
with a 3D Gaussian filter (FWHM 1 mm) along the
spatial dimensions and with a low pass filter (preserving
only the mean and the first four harmonics) along the
time dimension. A volume of interest containing the LV
cavity in all 12 images was manually defined. For each
image, the cavity volume was determined by applying a
threshold of 50% of the maximum value inside that
volume of interest.
Anesthetized rats also underwent cMRI with a 9.4-T
20-cm bore horizontal magnet using a linear resonator for
excitation combined with a 2 × 2-phased array coil for de-
tection (BRUKER Biospin, Ettlingen, Germany) and a
retrospectively gated FLASH sequence (INTRAGATEW,
BRUKER; repetition time (TR)/echo time (TE) = 7.6/1.8
ms, flip angle = 17°, matrix = 256 × 256, field of view
(FOV) = 6 × 6 cm, 10 to 12 1-mm-thick short axis slices
covering the LV, 15 frames reconstructed). To ensure
stable and reproducible results, physiological parameters
such as body temperature and respiratory and heart rates
were carefully monitored throughout the imaging session,
and it is noteworthy to mention that there was an interval
of 7 to 10 days between the micro-PET and cMRI scan. A
manual delineation of the endocardium, ignoring the
papillary muscles, was carried out using a homemade soft-
ware for cMRI [19]. The LVEF values were computed as
follows: LVEF = (EDV − ESV/EDV) × 100, where EDV
and ESV are end-diastolic volume and end-systolic
volumes, respectively.
Pig study
Myocardial infarction was induced in 25- to 30-kg do-
mestic pigs as previously described [20]. In brief, the left
anterior descending coronary artery was temporarily
occluded by a 90-min balloon inflation of a bare metal
stent distal to the first diagonal branch. Continuous
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during the whole procedure. Eight weeks later, gated
blood pool PET and MRI were performed. [18F]-(5)
(185 MBq) was administered via a venous catheter,
and a 60-min ECG-gated PET scan was acquired in
the list mode (HiRez Biograph 16, Siemens, Knoxville,
TN, USA). A low-dose CT scan was conducted for at-
tenuation correction. Based on the simultaneously
recorded ECG signal, the cardiac cycle was divided in
eight frames, and a PET sinogram was created from
the list mode data for each frame. From these sino-
grams, eight images were reconstructed using 2D
OSEM (five iterations and eight subsets) after Fourier
rebinning. LV volumes and EF were determined in
the same way as for the small animal study, i.e., by
applying a threshold of 50% of the maximum in a
manually defined volume of interest containing the
cavity. The person who analyzed the PET data was
blinded from the MRI results.
The MRI images were obtained in supine position on
a 3-T unit (TRIO, Siemens, Erlangen, Germany) with
ECG gating and during suspended respiration. A con-
tiguous stack of short-axis images covering the entire
ventricle was acquired with a 2D FLASH (fast low-angle
shot) sequence using retrospective gating and the follow-
ing imaging parameters: TR/TE = 25.45/2.39 ms, flip
angle = 14°, matrix = 170 × 208, FOV = 310 × 380 mm,
slice thickness = 6 mm, 40 cardiac phases, bandwidth
445 Hz/pixel). Volumes were determined by manual
contouring in the same manner as described for the rat
studies above.
All animal studies were approved by the Ethics
Committee for Animal Experimentation (KU Leuven,
Belgium) and were performed in accordance with the
Guide for Care and Use of Laboratory Animals
(NIH).Figure 1 Synthesis of [18F]-(3) and [11C]-(4). Reagents and conditions: (i)
(ii) CH3ONa, HCL 1 M, and (iii) (a) DMF, 1-bromo-2-fluoroethane, 70°C, 16 h
15 min.Results and discussion
Results
Chemistry and radiochemistry
The O-acetyl protected intermediate (1) was obtained by
treatment of 4-acetoxybenzoylchloride with 4-(2-ami-
noethyl-benzene)sulfonamide (AEBS) as described by
Kuhnast et al. [21]. Hydrolysis of the acetyl protecting
group resulted in the phenolic precursor (2) with a chem-
ical yield of 80%. Alkylation of precursor (2) with 1-bromo-
2-fluoro-ethane or 1-bromo-2-[18F]fluoroethane (18FEtBr)
resulted in the reference compound (3) and the radiola-
beled fluoroethoxy derivative [18F]-(3), respectively. The
11C-labeled methoxyderivative [11C]-(4) was obtained simi-
larly by alkylation of (2) with 11CH3I (Figure 1), and the
reference compound (4) was synthesized by acylation of
AEBS with 4-methoxybenzoyl chloride. Similarly, the other
small (radiolabeled) sulfonamide derivatives, [18F]-(5) and
[11C]-(6), were obtained by alkylation of commercially
available 4-hydroxybenzene-1-sulfonamide (HBS) with
18FEtBr and 11CH3I, respectively. The reference compound
of (5) has been synthesized similarly by alkylation of HBS
with 1-bromo-2-fluoroethane (Figure 2). The authentic
reference material (6) for [11C]-(6) was obtained commer-
cially. All tracers were obtained with good radiochemical
yield of 30% to 65% and high radiochemical purity (≥98%).
The identity of the radiotracers was confirmed by co-
elution with authentic reference compounds.
Log DpH 7.4, PSA, and Ki
Table 1 summarizes log D, polar surface area (PSA), and
the in vitro Ki data of reference compounds, along
with AAZ.
Whole blood analysis
The human whole blood analysis revealed that all four
studied tracers had a rapid uptake, and ≥90% of theAEBS, dichloromethane, pyridine for 72 h at room temperature,
; (b) DMF, Cs2CO3,
11CH3I, 90°C, 15 min; (c) DMF, Cs2CO3,
18FEtBr, 90°C,
Figure 2 Synthesis of [18F]-(5) and [11C]-(6). Reagents and conditions: (a) (i) AEBS, dichloromethane, pyridine for 72 h at room temperature.
(b) (i) (a) DMF, 1-bromo-2-fluoroethane, 70°C, 16 h; (b) DMF, NaOH 1 M, 11CH3I, 90°C, 15 min; (c) DMF, NaOH 1 M,
18FEtBr, 90°C, 15 min.
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min incubation at RT. Furthermore, the radiotracer
binding to carbonic anhydrases in RBCs was demon-
strated from competitive inhibition studies by incubating
the whole blood samples with radiotracers in the pres-
ence of the CA nonspecific inhibitor, AAZ, with final
concentrations ranging from 10 μM to 1 mM. Figure 3
shows a sigmoid dose response curve with a reduction
in the uptake of tracer (three- to eightfold) at concentra-
tions ranging from 200 to 500 μM of AAZ, indicating a
competitive binding of AAZ to CA I/II which is in
agreement with an earlier report [22].
Distribution of activity within blood
The activity incubated with the blood was distributed in
the RBC-rich sediment (92.5 ± 1.8%), and only 7.0 ±
1.6% and 0.5 ± 0.2% were found in the plasma-rich
supernatant and WBC-rich compartment, respectively.
Biodistribution studies
Biodistribution studies in mice (Table 2) demonstrated a
high blood pool retention of about ≥69% ID at 2 min p.i.
and ≥52% ID at 60 min p.i. for all tracers, except in the
case of [18F]-(3) where only 32% ID at 60 min p.i. wasTable 1 Ki of reference compounds (3 to 6) against
carbonic anhydrase isozymes hCA I and II
Compound Ki (nM)
a Log D cPSAd (Å2)
hCA Ib hCA IIb
(3) 96 8 1.13 99
(4) 390 20 1.19 99
(5) 30,850 336 0.32 69
(6) 24,700 422 0.42 69
AAZ 250 12 −1.5c 109
For CO2 hydration reaction at 20°C.
aStandard errors of the mean in the range
of 5% to 10% of the reported value (n = 3, different assays); bhuman (cloned)
isozymes; ccLog D; dcPSA = (calculated) polar surface area.observed. All the other organs (the lungs, heart, brain,
spleen, and pancreas) showed minimal tracer retention
at 60 min p.i. The clearance of tracers [18F]-(3) and
[18F]-(5) was mainly through the renal pathway (≥15%
ID in urine at 60 min p.i.), whereas for [11C]-(4) and
[11C]-(6), the clearance was mainly via the hepatobiliary
pathway (12% to 19% ID in the intestines at 60 min p.i.).
In the carcass, about 16% to 29% ID was observed at 2
and 60 min p.i. for all tracer agents; this is probably due
to the activity associated with the residual blood in the
carcass.Small animal imaging studies
In view of the biodistribution results and the longer
half-life of fluorine-18 (110 min) compared with
carbon-11 (20 min), further imaging studies were
performed with [18F]-(5). A proof-of-concept in vivo
visualization of blood pool activity was carried out
by acquiring a 1-h dynamic micro-PET scan in rats.
The PET data revealed a high blood pool activity in
the heart and excellent visualization of all major
blood vessels with minimal leakage of tracer to the
extravascular compartment (Figure 4).
The time activity curves in rats (Figure 5) show that
large blood pool organs such as the liver, spleen, and
kidneys had a lower tracer uptake and retention com-
pared with the heart (SUV of 2.5). The average SUV
ratios of heart-to-spleen, heart-to-liver, and heart-to-
kidney were found to be 2.3, 4, and 2.5 respectively, with
an excellent target-to-background activity ratio. The
LVEF values with micro-PET for rats 1 and 2 were found
to be 75% and 61% at rest and under pharmacological
stress 84% and 85%, respectively. Similarly, using cMRI,
the LVEF values were found to be 53% and 73% at rest
and under pharmacological stress 81% and 82%, respect-
ively (Figure 6).
Figure 3 Uptake of [18F]-(3), [11C]-(4), [18F]-(5), and [11C]-(6) in human RBCs versus AAZ concentration. Data are expressed as percentage
of radioactivity in the cell fractions.
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Whole body imaging obtained 60 min after tracer injection
reveals high activity in the left and right atria and ventricles,
in the spleen, and in all major blood vessels (Figure 7a).
Similar to small animal studies, quantitative evaluation
of LV volumes and EF with PET shows a good agree-
ment with values obtained by cMRI (Figure 7b).Table 2 Biodistribution of [18F]-(3), [11C]-(4), [18F]-(5), and [11C
Organs [18F]-(3)
2 min 60 min 2
Percentage of ID Urine 0.2 ± 0.1 15.9 ± 6.0 0.4
Kidneys 10.6 ± 0.8 2.8 ± 0.1 8.1
Liver 15.8 ± 1.5 8.3 ± 1.2 8.4
Spleen + pancreas 1.3 ± 0.2 0.9 ± 0.3 0.6
Lungs 2.3 ± 0.5 0.7 ± 0.3 4.9
Heart 0.8 ± 0.0 0.2 ± 0.2 0.5
Intestines 5.9 ± 0.8 18.6 ± 1.0 3.6
Stomach 0.7 ± 0.1 1.9 ± 1.3 0.7
Brain 0.2 ± 0.0 0.2 ± 0.1 0.2
Blood 71.0 ± 4.3 31.7 ± 2.1 90.5
Carcass 18.10 ± 2.32 31.35 ± 3.67 17.6
SUV Kidneys 5.6 ± 0.6 1.6 ± 0.1 4.3
Liver 3.2 ± 0.2 1.7 ± 0.3 1.5
Spleen 1.6 ± 0.2 1.1 ± 0.3 0.9
Lungs 3.5 ± 1.0 1.1 ± 0.4 6.0
Heart 2.3 ± 1.3 0.5 ± 0.4 1.2
Brain 0.2 ± 0.0 0.1 ± 0.0 0.2
Blood 10.1 ± 0.6 4.5 ± 0.3 12.9
This activity is at 2 and 60 min p.i. Data are expressed as mean ± standard error (nDiscussion
The aim of this study was to develop PET tracers for
in vivo labeling of RBCs and to evaluate their potential
application for assessing cardiac function. CA isozyme
II, an efficient catalyst involved in the physiological reac-
tion of reversible hydration of carbon dioxide to bicar-
bonate and a proton, is abundantly present in the RBCs]-(6) in normal NMRI mice
[11C]-(4) [18F]-(5) [11C]-(6)
min 60 min 2 min 60 min 2 min 60 min
± 0.1 4.4 ± 2.7 0.3 ± 0.1 10.0 ± 5.0 0.3 ± 0.1 4.8 ± 0.3
± 1.3 4.1 ± 0.3 4.1 ± 0.8 3.7 ± 1.1 3.7 ± 0.1 4.1 ± 0.6
± 0.7 9.2 ± 1.1 6.0 ± 1.1 4.0 ± 0.2 6.9 ± 0.4 6.1 ± 0.5
± 0.1 0.8 ± 0.1 1.1 ± 0.1 0.9 ± 0.4 1.2 ± 0.1 2.3 ± 0.6
± 2.5 4.2 ± 1.1 7.3 ± 3.9 1.8 ± 0.6 6.3 ± 2.7 3.1 ± 1.4
± 0.1 0.5 ± 0.1 0.6 ± 0.1 0.6 ± 0.2 0.7 ± 0.2 0.4 ± 0.1
± 1.3 12.4 ± 0.8 2.9 ± 0.4 9.6 ± 2.8 5.2 ± 0.9 19.3 ± 1.0
± 0.1 2.6 ± 0.3 0.8 ± 0.2 4.2 ± 3.1 1.5 ± 0.3 2.4 ± 0.2
± 0.0 0.3 ± 0.0 0.3 ± 0.0 1.0 ± 0.1 0.7 ± 0.1 1.5 ± 0.1
± 5.9 72.5 ± 7.6 106.3 ± 5.2 71.0 ± 14.5 83.4 ± 7.7 49.7 ± 4.8
± 1.5 21.2 ± 2.8 18.8 ± 1.6 22.4 ± 1.5 28.4 ± 2.0 26.1 ± 1.0
± 0.7 2.5 ± 0.2 3.1 ± 0.6 2.5 ± 0.4 2.4 ± 0.3 2.4 ± 0.2
± 0.2 1.9 ± 0.3 1.4 ± 0.3 1.0 ± 0.1 1.5 ± 0.1 1.4 ± 0.2
± 0.1 1.1 ± 0.2 2.1 ± 0.7 2.2 ± 0.8 1.9 ± 0.8 2.4 ± 0.4
± 1.6 4.7 ± 0.7 9.3 ± 2.9 3.8 ± 0.4 6.2 ± 2.1 3.5 ± 1.1
± 0.2 1.0 ± 0.3 1.6 ± 0.4 1.7 ± 0.5 1.6 ± 0.4 0.9 ± 0.1
± 0.0 0.2 ± 0.0 0.5 ± 0.1 1.4 ± 0.2 0.7 ± 0.1 1.1 ± 0.1
± 0.8 10.4 ± 1.1 17.3 ± 2.5 11.1 ± 1.2 11.9 ± 1.1 7.1 ± 0.7
= 3).
AB
Figure 4 Maximum intensity projection images. (A) Maximum intensity projection micro-PET image after administration of 37 MBq of [18F]-(5),
showing high activity in the heart and large blood vessels. (B) Maximum intensity projection detail of the heart showing high activity in the left
and right ventricles of the heart and in all of the major blood vessels.
Figure 5 Time activity curves of [18F]-(5) in various organs versus myocardial blood pool activity. Time activity curves of [18F]-(5) in the
liver, spleen, and kidneys of a Wistar rat in comparison with the myocardial blood pool activity illustrating good retention of tracer in the blood
pool compartment with excellent target-to-background ratios.








Figure 6 Retrospective ECG-gated micro-PET and cMRI images of a representative rat. (A, E, I) End-diastolic and (B, F, J) end-systolic
frames during rest on micro-PET and cMRI, respectively. (C, G, K) End-diastolic and (D, H, L) end-systolic images during pharmacological stress in
the same rat. The lower ESV in stress condition is clearly observed on both micro-PET and cMRI. (left panel: PET maximum intensity projection
images, central panel: axial MRI images, right panel: axial PET images).
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fonamide derivatives [23]. Several highly specific and po-
tent inhibitors targeting CA II were reported in the
literature [24]. Here, we synthesized 11C and 18F sulfona-
mide derivatives in a straightforward reaction with good
radiochemical yield and purity. To penetrate the cellular
membrane and to interact with CA II localized in the
cytosol, the tracer agents need to be lipophilic and have
a PSA < 90 Å2 [25,26]. The calculated PSA was found to
be 69 Å2 for [18F]-(5) and [11C]-(6). Due to the add-
itional amide bond, the cPSA value increased to 99 Å2Figure 7 Coronal maximum intensity projection of the pig model and
intensity projection of the pig model reveals high activity in the left and rig
(b) Representative image illustrating delineation of ESV and EDV on PET an
quantification of LV volumes and EF.for [18F]-(3) and [11C]-(4). In order to be efficient tracers
for in vivo labeling of erythrocytes, it is critical that the
tracer agents rapidly diffuse in the RBC where they bind
to CA I/II isozymes after intravenous injection. The frac-
tion of the tracer which is not bound to the RBCs should
be minimal at the time that the injection bolus reaches
organs such as the liver or kidneys to avoid clearance
through these excretory organs. It is thus anticipated
that the labeling efficiency will be higher in larger spe-
cies as not only a larger excess of CA I/II is available,
but also the relative cardiac output is lower and thequantitative evaluation with PET and MRI. (a) Coronal maximum
ht atria and ventricles, in the spleen, and in all major blood vessels.
d cMRI. A good agreement was observed between PET and MRI for
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much slower blood clearance in man versus rats for the
radioiodinate sulfonamides reported by Singh et al. [14].
The data of Table 1 show that the investigated com-
pounds demonstrated lower inhibition constants for CA
II and higher CA II vs. CA I specificity of compounds
(3) and (4) versus compounds (5) and (6). Human whole
blood analysis indicated that the tracer agents were
retained ≥90% in RBCs at 10 and 60 min post incubation
at room temperature, suggesting their membrane-
permeable nature. Further experiments showed that
more than 90% of the activity is confined to the RBCs
and not to other constituents of the blood. In addition,
the competition study with CA inhibitor AAZ indicates
that the binding to RBCs is due to specific interaction
with CA I/II. Biodistribution studies in mice showed sig-
nificant accumulation of all tested tracer agents in the
blood pool at 2 min with a relative decrease of 23% to
53% of the blood pool-associated activity at 60 minutes
p.i. Compound [18F]-(3) shows only 32% ID at 60 min
p.i. in the blood in contrast with its potent inhibitory
activity against CA II (Ki = 8 nM) and its PSA value which
is comparable to that of [11C]-(4) for which the blood
retention at 60 min p.i. was twice as high (68%). The
higher urinary excretion of 18F-labeled compounds com-
pared to their carbon-11 analogs may be caused by
urinary excretion of polar radiometabolites which may not
be generated in the case of the 11C-labeled compounds.
The potential application to calculate LVEF values in rats
and pigs was demonstrated in a proof-of-concept study
with [18F]-(5). As shown in Figure 5, the highest SUV in
rats was observed over the heart region for which the SUV
value at 60 min amounted to 75% of the 2-min value. Fur-
thermore, it is noteworthy that no bone uptake was
observed, indicating the absence of in vivo defluorination.
The presence of free fluoride would have an adverse effect
with high background activity in the upper skeleton and
would result in inaccurate quantification due to partial vol-
ume effects. The potential application of the tracer for
assessing cardiac function was demonstrated by measuring
the global parameters (LV volumes and EF) in rest and
stress conditions using ECG micro-PETand cMRI. In stress
condition, there was a good correlation of LVEF values be-
tween PET and cMRI. In rest condition, the obtained LVEF
values were somewhat more variable for both techniques.
This discrepancy can be attributed to subtle changes in the
physiology of the animal even though every effort was made
to obtain comparable study conditions, e.g., using a com-
mon anesthesia protocol.
In the pig model of myocardial infarction, an excellent
agreement was found between the EF and LV values
obtained with MRI and PET, respectively. The whole
body image (Figure 7a) largely reflects blood pool with
high activity in the heart and major blood vessels. Incontrast to the human spleen, the pig's spleen stores
about 20% of its total number of RBCs which explains
the high activity observed in this organ [27]. A small
amount of activity was also observed in the bladder.
In view of the low extravascular activity in the abdomen,
this tracer can potentially be used for PET visualization of
gastrointestinal bleeding and hemangioma with higher
resolution and sensitivity compared with SPECT using
technetium-labeled erythrocytes. Labeling of the RBCs
with [18F]-(5) has the advantage that it can potentially be
used for any species, and in addition, it does not require
any manipulation of blood.
Both PET and cMRI endure certain limitations, espe-
cially in terms of manual delineation of ESV and EDV,
which is subjected to a risk of partial volume effect on
PET, and for cMRI, there is a risk for misdelineation of
contours at the myocardium. Nevertheless, the study
demonstrated the ability of the synthesized PET tracers
to allow assessment of LVEF and volumes in rats and
pigs. As mentioned above, a slower clearance from the
blood pool compartment of these tracers in humans
compared with rats and pigs is anticipated so that fur-
ther clinical evaluation of this compound is warranted.
Conclusions
Our results clearly demonstrate that the developed 11C-
or 18F-labeled sulfonamide derivatives can be used for
blood pool imaging using PET. Our initial in vitro and
in vivo evaluation indicates the tracer's ability to effi-
ciently radiolabel RBCs in vivo. Biodistribution and im-
aging studies revealed mainly blood pool activity with
minimal background signal. In a proof-of-concept study,
we demonstrated the applicability of ECG-gated PET to
assess cardiac function and volumes in rats and in a pig
model of myocardial infarction. Further studies are war-
ranted to fully exploit the potential of this tracer and
translate it to clinical applications.
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